ENTA vs ACHV vs AGIO vs ARQT vs PRTA

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Enanta Pharmaceuticals, Inc. (ENTA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcutis Biotherapeutics, Inc.

(ARQT) delivered a total return of -30. 2%, compared to -72. 2% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: ARQT returned +10. 9% versus ACHV's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Achieve Life Sciences, Inc. 's 2. 14β — meaning ACHV is approximately 123% more volatile than PRTA relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Achieve Life Sciences, Inc.

(ACHV) is the more profitable company, earning 0. 0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACHV leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Prothena Corporation plc (PRTA) trades at 45.

3x forward P/E versus 90. 8x for Arcutis Biotherapeutics, Inc. — 45. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENTA: 232. 9% to $48. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Achieve Life Sciences, Inc. (ACHV) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -70. 8%, ACHV: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENTA is a small-cap quality compounder stock; ACHV is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; ARQT is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.